This study is in progress, not accepting new patients
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
Summary
- Eligibility
- for people ages 18-55 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Bruce Cree
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Bruce Cree
Bruce Cree, MD, PhD, MAS is a Professor of Clinical Neurology and is the George A. Zimmermann Endowed Professor in Multiple Sclerosis in the Department of Neurology at the University of California San Francisco. Dr. Cree completed his MD and PhD in Biochemistry at UCSF. His neurology residency training was at Columbia University.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT01247324
- Phase
- Phase 3 Multiple Sclerosis Research Study
- Study Type
- Interventional
- Participants
- At least 821 people participating
- Last Updated